Login to Your Account

Investors Attracted Back

RNA Interference Therapies Are Enjoying a Renaissance

By Peter Winter

Monday, November 18, 2013

Gene silencing is firmly back on the R&D radar screen in the fight to combat intractable disease after a hiatus of several years. Promising results from early clinical results have begun to attract investors into the space again with well over $200 million poured into this sector so far in 2013; and public companies developing RNA-based drugs have seen their share prices soar.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription